Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Broadcom

Domino's Pizza

DexCom

Fair Isaac

Cheniere Energy

MarketAxess Holdings

Netflix

TransDigm

United Rentals

The huge winners of the 2010s include the stocks of two popular consumer goods companies and a Warren Buffett stock.

The 10 Best Performing Stocks of the Decade

Impressive long-term study results for an important product eased investor concerns over the tie-up between Exact Sciences and Genomic Health.

Here's Why Exact Sciences Gained 14.1% in December

Neurocrine Biosciences

Novanta

Here's your proof for taking a long-term approach to investing.

The Five Best Stocks of the Past Decade

Myriad Genetics

Which stock wins in a battle between these two genomic testing leaders?

Better Buy: Exact Sciences vs. Myriad Genetics

Pfizer announced an expedited FDA review for its drug to treat colorectal cancer, which Exact Sciences’ lead diagnostic test also targets.

Exact Sciences Should Benefit from Pfizer’s News Today

ABIOMED

Align Technology

Jazz Pharmaceuticals

These ten growth stocks saw the highest percentage growth over the last decade, and some remain unknown to investors despite huge increases.

10 Best-Performing Growth Stocks of the 2010s

Guardant Health Inc

Guardant Health (blood-based liquid biopsies) and Exact Sciences (stool-based colorectal cancer detection) have both announced plans to compete directly in each other's core market.

High Growth Non-Invasive Cancer Test Technology: Guardant Health Vs. Exact Sciences

Exact Sciences just completed its multibillion-dollar acquisition of Genomic Health, setting the stage for the company’s future.

Is Exact Sciences Stock a Buy? (EXAS)

Illumina

Which stock wins in a one-on-one matchup between these two genomics revolution leaders?

Better Buy: Exact Sciences vs. Illumina

Exact Sciences Corp (EXAS) CEO Kevin Conroy on Q3 2019 Results - Earnings Call Transcript

Is  (EXAS) Outperforming Other Medical Stocks This Year?

Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?

During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.

Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?

bluebird bio

Bristol-Myers

These drug stocks are among the best to buy now because each is making progress in the fight against cancer. Here's what you should know about each.

3 Cancer-Fighting Drug Stocks to Buy Right Now

Since the start of September, the luster has disappeared from Exact Sciences' stock. This pullback provides an opportunity to own a company that is growing on multiple levels.

A Cancer Diagnostics Company You Should Own Today

Exact Sciences Corporation has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Exact Sciences Corporation Enters Oversold Territory

Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.

Exact Sciences Gets FDA Nod for Label Expansion of Cologuard

Fitbit

United States Steel

Chewy

After a quiet weekend on the macro news front that was preceded by a less-than-eventful quadruple expiration, the PreMarket Prep crew dedicated much of Monday's show to analyst rating changes.

PreMarket Prep Recap: Fitbit, Exact Sciences Headlines; US Steel Downgrade 'A Bit Late To The Party'

Cologuard continues to be a phenomenal success for Exact Sciences.

Exact Sciences Is An Attractive Cancer Diagnostics Pick

Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.

3 Cancer Treatment Stocks to Enrich Your Portfolio

EXACT Sciences stock has pulled back to a historically bullish trendline

Signal Says EXACT Sciences Stock Can Stay Hot

Genomic Health

NeoGenomics

Invitae

It was a great month to be a genetic testing company.

Here's Why Genetic Testing Stocks Rose as Much as 25.4% in July

When Kevin Conroy was recruited for the top job at Exact Sciences Corp. (NASDAQ:EXAS), he knew it would require a leap of faith to take on the role.

Acquisition Boosts Exact Sciences’ Role in Cancer Diagnostics

CFO of Exact Sciences Corp (30-Year Financial, Insider Trades) Jeffrey Thomas Elliott (insider trades) sold 9,845 shares of EXAS on 07/30/2019 at an average price of $105.6 a share.

Exact Sciences Corp (EXAS) CFO Jeffrey Thomas Elliott Sold $1 million of Shares

Boyd Gaming

Lionheart Holdings

LivePerson

Moderna

Nexstar Media Group

Open Text

Which top stocks are Wall Street analysts the most bullish on? These strong buy stocks deserve a spot on your watch list.

7 Strong Buy Stocks the Street Loves

At first glance, an acquisition announcement looked like the wrong deal.

News for Exact Sciences Stock (EXAS)